LYNPARZA (olaparib) Shows Significant Survival Benefit in …
AstraZeneca and Merck have shared new results from the OlympiA Phase 3 trial that highlight the positive impact of LYNPARZA (olaparib) on patients with germline BRCA-mutated (gBRCAm) HER2-negative high-risk early breast cancer. These findings were presented at the 2024 San Antonio Breast Cancer Symposium and were recently published in The New England Journal of Medicine.
Judy E. Garber, a key investigator in the trial, expressed excitement about the long-term data, highlighting the continued survival benefits for patients even after six years of treatment. The results show that LYNPARZA has delivered sustained, clinically meaningful improvements in overall survival, invasive disease-free survival, and distant disease-free survival. This is especially good news for patients with high-risk early breast cancer who have the gBRCAm mutation.
Breast cancer affects millions of people worldwide, with a significant percentage diagnosed at an early stage of the disease. Approximately 5-10% of breast cancer patients have BRCA mutations, making them eligible for treatments like LYNPARZA.
Susan Galbraith of AstraZeneca emphasized the groundbreaking nature of LYNPARZA as the first and only PARP inhibitor to demonstrate a survival benefit for patients with gBRCAm, HER2-negative, high-risk early-stage breast cancer. The results of the OlympiA study confirm the long-term efficacy of LYNPARZA, offering hope to patients facing this challenging form of breast cancer.
Dr. Eliav Barr from Merck Research Laboratories also highlighted the significance of LYNPARZA as a crucial treatment option for individuals dealing with this aggressive type of breast cancer. The study results showed a 28% decrease in the risk of death and a notable increase in survival rates for patients taking LYNPARZA compared to a placebo.
LYNPARZA was consistent in delivering positive outcomes across various measures, including a 35% reduction in the risk of invasive breast cancer recurrence, second cancers, or death. The drug also showed a 35% reduction in distant disease recurrence or death. These results underscore the importance of early diagnosis and treatment with LYNPARZA for eligible patients with gBRCAm mutations.
